vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是STURM RUGER & CO INC的1.0倍（$156.4M vs $151.1M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs 3.6%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 5.1%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
BCRX vs RGR — 直观对比
营收规模更大
BCRX
是对方的1.0倍
$151.1M
营收增速更快
BCRX
高出3.8%
3.6%
两年增速更快
BCRX
近两年复合增速
5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $151.1M |
| 净利润 | — | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 13.6% | 2.3% |
| 净利率 | — | — |
| 营收同比 | 7.5% | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.00 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRGR
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $151.1M | ||
| Q3 25 | $159.4M | $126.8M | ||
| Q2 25 | $163.4M | $132.5M | ||
| Q1 25 | $145.5M | $135.7M | ||
| Q4 24 | $131.5M | $145.8M | ||
| Q3 24 | $117.1M | $122.3M | ||
| Q2 24 | $109.3M | $130.8M |
净利润BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | $1.6M | ||
| Q2 25 | $5.1M | $-17.2M | ||
| Q1 25 | $32.0K | $7.8M | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | $4.7M | ||
| Q2 24 | $-12.7M | $8.3M |
毛利率BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 17.8% | ||
| Q3 25 | 98.6% | 15.1% | ||
| Q2 25 | 98.3% | 3.9% | ||
| Q1 25 | 96.9% | 22.0% | ||
| Q4 24 | 95.4% | 22.8% | ||
| Q3 24 | 97.3% | 18.5% | ||
| Q2 24 | 98.4% | 22.3% |
营业利润率BCRXRGR
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 2.3% | ||
| Q3 25 | 18.6% | -2.7% | ||
| Q2 25 | 18.2% | -15.6% | ||
| Q1 25 | 14.6% | 6.2% | ||
| Q4 24 | -3.4% | 7.8% | ||
| Q3 24 | 6.6% | 3.1% | ||
| Q2 24 | 8.0% | 6.9% |
净利率BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | 1.2% | ||
| Q2 25 | 3.1% | -13.0% | ||
| Q1 25 | 0.0% | 5.7% | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | 3.9% | ||
| Q2 24 | -11.6% | 6.3% |
每股收益（稀释后）BCRXRGR
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $0.22 | ||
| Q3 25 | $0.06 | $0.10 | ||
| Q2 25 | $0.02 | $-1.05 | ||
| Q1 25 | $0.00 | $0.46 | ||
| Q4 24 | $-0.13 | $0.62 | ||
| Q3 24 | $-0.07 | $0.28 | ||
| Q2 24 | $-0.06 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $283.8M |
| 总资产 | $465.1M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRGR
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $92.5M | ||
| Q3 25 | $212.9M | $80.8M | ||
| Q2 25 | $260.0M | $101.4M | ||
| Q1 25 | $295.1M | $108.3M | ||
| Q4 24 | $320.9M | $105.5M | ||
| Q3 24 | $96.8M | $96.0M | ||
| Q2 24 | $78.4M | $105.6M |
股东权益BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $283.8M | ||
| Q3 25 | $-387.9M | $279.6M | ||
| Q2 25 | $-421.6M | $289.3M | ||
| Q1 25 | $-451.9M | $321.5M | ||
| Q4 24 | $-475.9M | $319.6M | ||
| Q3 24 | $-468.6M | $314.9M | ||
| Q2 24 | $-475.6M | $321.5M |
总资产BCRXRGR
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $342.0M | ||
| Q3 25 | $446.4M | $342.3M | ||
| Q2 25 | $457.2M | $349.5M | ||
| Q1 25 | $480.0M | $379.0M | ||
| Q4 24 | $490.4M | $384.0M | ||
| Q3 24 | $491.3M | $373.5M | ||
| Q2 24 | $472.4M | $376.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $15.5M |
| 自由现金流经营现金流 - 资本支出 | — | $12.3M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $15.5M | ||
| Q3 25 | $41.6M | $12.9M | ||
| Q2 25 | $41.3M | $14.7M | ||
| Q1 25 | $-27.5M | $11.1M | ||
| Q4 24 | $-5.2M | $20.0M | ||
| Q3 24 | $8.2M | $9.4M | ||
| Q2 24 | $-1.4M | $18.7M |
自由现金流BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $12.3M | ||
| Q3 25 | $40.3M | $7.0M | ||
| Q2 25 | $41.1M | $9.1M | ||
| Q1 25 | $-27.7M | $10.0M | ||
| Q4 24 | $-5.9M | $16.4M | ||
| Q3 24 | $8.2M | $2.6M | ||
| Q2 24 | $-1.5M | $10.1M |
自由现金流率BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 8.2% | ||
| Q3 25 | 25.3% | 5.5% | ||
| Q2 25 | 25.2% | 6.9% | ||
| Q1 25 | -19.0% | 7.4% | ||
| Q4 24 | -4.5% | 11.2% | ||
| Q3 24 | 7.0% | 2.1% | ||
| Q2 24 | -1.4% | 7.7% |
资本支出强度BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.1% | ||
| Q3 25 | 0.8% | 4.6% | ||
| Q2 25 | 0.1% | 4.2% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.5% | 2.5% | ||
| Q3 24 | 0.1% | 5.5% | ||
| Q2 24 | 0.1% | 6.6% |
现金转化率BCRXRGR
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | 8.15× | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
